> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Merck Lifts Its 2026 Profit Outlook To $2.77-$2.82 A Share Despite A Third-Quarter Earnings Dip
- URL: https://www.bullished.co/merck-lifts-its-2026-profit-outlook-to-2-77-2-82-a-share-despite-a-third-quarter-earnings-78ed644a/
- Published: 2026-10-29T10:52:12.000Z
- Updated: 2026-10-29T10:52:12.000Z
- Description: Third-quarter adjusted earnings per share fell to $2.49 from $2.58, yet the drugmaker raised its full-year range.
- Author: Matteo Parrino
- Tags: Earnings, MRK, Industry: Healthcare

[Merck](https://www.bullished.co/tag/mrk/) raised its full-year adjusted earnings forecast to [$2.77 to $2.82](https://www.businesswire.com/news/home/20261029138599/en/Merck-Co.-Inc.-Rahway-N.J.-USA-Announces-Third-Quarter-2026-Financial-Results-Highlights-Multiple-Milestones-Advancing-Broad-Diverse-Pipeline?ref=bullished.co) a share, up from $2.66 to $2.76, even as third-quarter adjusted earnings slipped to [$2.49 from $2.58](https://www.sec.gov/Archives/edgar/data/0000310158/000110465926119825/tm2628203d1%5Fex99-1.htm?ref=bullished.co) a year earlier, the company said Thursday in an [8-K filing](https://www.sec.gov/Archives/edgar/data/0000310158/000110465926119825/tm2628203d1%5F8k.htm?ref=bullished.co). A one-time $0.12-per-share licensing charge and heavier research and launch spending weighed on the quarter.

## Sales up, earnings down

Merck, a health care company that makes prescription medicines, vaccines and animal health products, reported third-quarter [sales of $18.1 billion](https://www.businesswire.com/news/home/20261029138599/en/Merck-Co.-Inc.-Rahway-N.J.-USA-Announces-Third-Quarter-2026-Financial-Results-Highlights-Multiple-Milestones-Advancing-Broad-Diverse-Pipeline?ref=bullished.co), up 5% (4% excluding currency effects). Earnings per share under standard accounting fell 12% to $2.04, from $2.32.

Both the standard and adjusted figures carry the $0.12 charge tied to a global license agreement with SciBrunch for MK-2690, a preclinical oral cancer drug candidate. Last year's third quarter included a $0.10-per-share milestone payment to LaNova Medicines.

Research and development spending rose 7% to $4.5 billion, including a $400 million SciBrunch charge, offset in part by a $200 million reduction tied to a funding agreement with Blackstone Life Sciences. Selling, general and administrative costs rose 10% to $2.9 billion on higher administrative and launch promotion costs. Standard gross margin fell to 72.9% from 77.7%.

## Keytruda and Winrevair carry the quarter

Keytruda and its subcutaneous version Keytruda Qlex brought in $8.6 billion, up 6%, including $830 million from Qlex. Winrevair sales rose 93% to $694 million, and Welireg climbed 56% to $307 million.

Gardasil sales rose 14% to $1.995 billion. Januvia and Janumet fell 39% to $380 million on generic competition, and Bridion sank 67% to $144 million for the same reason. Animal Health sales rose 4% to $1.7 billion.

The company said purchase timing added about $550 million to pharmaceutical sales growth.

## What the new guidance says

Merck now expects 2026 sales of $66.8 billion to $67.3 billion, narrowing a range that began at $66.3 billion. Its adjusted tax rate forecast dropped to 32.0% to 33.0% from 35.0% to 36.0%, and operating expense guidance rose to $42.4 billion to $42.9 billion.

The EPS range includes one-time charges of $3.62 a share for the Cidara acquisition, $2.31 for Terns and the new $0.12 for SciBrunch, which was not previously in the outlook.

Chairman and CEO Robert M. Davis said the oncology advances shown at ESMO "further clinically de-risk the substantial long-term opportunity of our late-phase pipeline." The FDA has set a June 15, 2027 target decision date for sac-TMT in endometrial cancer, though Merck said it is in talks with the agency and hopes for earlier approval.

Merck holds its earnings call at 9 a.m. EDT Thursday.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Merck & Co., Inc. (MRK)](https://www.sec.gov/Archives/edgar/data/0000310158/000110465926119825/tm2628203d1%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2628203d1\_ex99-1.htm — Merck & Co., Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000310158/000110465926119825/tm2628203d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2628203d1\_ex99-2.htm — Merck & Co., Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000310158/000110465926119825/tm2628203d1%5Fex99-2.htm?ref=bullished.co) — SEC EDGAR
- [Pharma giants Merck, Eli Lilly face earnings health check (MRK:NYSE) | Seeking Alpha](https://seekingalpha.com/news/4659100-pharma-giants-merck-eli-lilly-face-earnings-health-check?ref=bullished.co) — seekingalpha.com
- [Merck (MRK) Gains Fresh Oncology Backing As Valuation Debate Heats Up](https://finance.yahoo.com/healthcare/articles/merck-mrk-gains-fresh-oncology-031149136.html?ref=bullished.co) — Yahoo Finance
- [Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck’s Q3 Results on Oct. 29](https://finance.yahoo.com/healthcare/articles/beyond-keytruda-critical-pipeline-metrics-153112087.html?ref=bullished.co) — Yahoo Finance
- [Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts](https://finance.yahoo.com/healthcare/articles/merck-highlights-phase-iii-cancer-000417837.html?ref=bullished.co) — Yahoo Finance
- [Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline](https://www.businesswire.com/news/home/20261029138599/en/Merck-Co.-Inc.-Rahway-N.J.-USA-Announces-Third-Quarter-2026-Financial-Results-Highlights-Multiple-Milestones-Advancing-Broad-Diverse-Pipeline?ref=bullished.co) — businesswire.com

### More on Merck

- [Merck Elects Paul Diaz, Ex-CEO Of Myriad Genetics And Kindred Healthcare, To 14-Member Board](https://www.bullished.co/merck-elects-paul-diaz-ex-ceo-of-myriad-genetics-and-kindred-healthcare-to-14-member-board-a4117b90/)

[All Merck (MRK) coverage →](https://www.bullished.co/tag/mrk/)